On Thursday, Shares of Wells Fargo & Company (NYSE:WFC), gained 0.30% to $56.89.
Wells Fargo & Company declared recently that Michael J. “Mike” Heid, executive vice president and head of Wells Fargo Home Lending, will retire after nearly 28 years with the company and 11 years leading the mortgage division. Effective Oct. 1, 2015, Franklin Codel, executive vice president and presently head of Mortgage Production, will succeed Heid as head of Wells Fargo Home Lending.
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Shares of AbbVie Inc. (NYSE:ABBV), declined -0.31% to $68.54, during its last trading session.
AbbVie on Wednesday said its experimental treatment for a form of leukemia associated with a gene mutation met its main aim in a mid-stage trial and that the company would seek U.S. approval of the medicine, which analysts have said has blockbuster sales potential, according to Reuters.
AbbVie, developing the drug venetoclax with Switzerland’s Roche Holding AG, said it would unveil data from the Phase II trial at an forthcoming medical meeting and will seek U.S. marketing approval for the product this year.
The drug was tested in patients with chronic lymphocytic leukemia (CLL) who had a so-called 17p gene deletion that has been associated with aggressive cancer and survival of less than 2 to 3 years after diagnosis. The trial comprised of patients with relapsed or advanced CLL, or those who had formerly been untreated. Reuters Reports
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Finally, MetLife, Inc. (NYSE:MET), ended its last trade with 0.35% gain, and closed at $54.37.
MetLife the largest U.S. life insurer, said its exposure to fixed-income energy investments fell to $14 billion at June 30 from $14.9 billion at the end of March, according to Bloomberg.
The latest figure comprises $13.8 billion of securities and $210 million of credit-default swaps, MetLife said Thursday in a regulatory filing. Unrealized gains on the holdings narrowed to $852 million at the end of June from $1.2 billion three months earlier. Bloomberg Reports
MetLife, which has a portfolio of about $500 billion, has been increasing disclosure of investments tied to potentially risky regions or industries. In recent quarters, the insurer stated reducing holdings in Russia and Ukraine. Bloomberg added.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
